CAS: 624-84-0; Formylhydrazine

上下游产品

CAS号109-94-4 甲酸乙酯 | CAS号107-31-3 甲酸甲酯 | CAS号64-18-6 甲酸 | CAS号67-56-1 甲醇 | CAS号7727-37-9 氮气 | CAS号10570-40-8 4-甲基-1,2,4-三唑 | CAS号3880-50-0 1-甲酰基-2-亚异丙基肼 | CAS号5373-72-8 3-巯基-4-苯基-1,2,4-三唑 | CAS号3451-51-2 2-甲基-1,3,4-恶二唑 | CAS号18039-42-4 5-苯基四氮唑 | CAS号188113-56-6 4-hexadecyl-1,2... | CAS号102-08-9 二苯基硫脲 | CAS号27104-95-6 4-丙基-4H-1,2,4-噻唑 | CAS号27105-98-2 4-乙基-4H-1,2,4-三...

甲酸乙酯置于肼体系中,用 乙醇 作为反应溶剂,化学反应生成 甲酰肼
参考文献:新型具有血管收缩活性的肼基丁烷的合成
标题:新型具有血管收缩活性的肼基丁烷的合成
摘要:合成了一系列与胍乙啶系列的胍具有结构相似性的酰肼.肼az升高血压的观察结果导致他们被筛选为鼻充血剂.活性最高的化合物3-(六氢-1H-氮杂环庚烷)丙二酸酰肼二盐酸盐的效力低于去氧肾上腺素盐酸盐.
DOI:10.1002/jps.2600590121

专利信息

专利号:US-7514559-B2
优先权日:2004-03-22
标题 :Catalyst for synthesis of 2- and 4-picolines
发明人：DUTTA PASHUPATI; ROY SUBHASH CHANDRA; ROY SHYAM KISHORE; GOSWAMI TARUN KANTI
权利人:COUNCIL SCIENT IND RES
摘要:The present invention provides a catalyst composite for the synthesis of 2- and 4-picolines and a process for the preparation thereof and use thereof for the synthesis of 2- and 4-Picolines.

专利号:US-6844434-B2
优先权日:2001-01-18
标题 :Synthesis of temozolomide and analogs
发明人：KUO SHEN-CHUN
权利人:SCHERING CORP
摘要:This invention relates to a novel process for the synthesis of temozolomide, an antitumor compound, and to intermediates useful in this novel process.

专利号:US-2013012706-A1
优先权日:2010-03-01
标 题 :Methods and Intermediates for the Synthesis of 4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazines
发明人：HUMMERSONE MARC GEOFFERY; COUSIN DAVID
权利人:PHARMINOX LTD; HUMMERSONE MARC GEOFFERY; COUSIN DAVID
摘要:The present invention provides a compound of general formula (II), or a salt or solvate thereof: n n n n n n n n n n n n wherein n A is independently -A 1 , -A 2 , -A 3 , -A 4 , -A 5 , -A 6 , or -A 7 , wherein:n -A 1 is independently C 5-12 heteroaryl, and is optionally substituted; -A 2 is independently thioamido or substituted thioamido; -A 3 is independently imidamido, substituted imidamido, N-hydroxyimidamido, or substituted N-hydroxyimidamido; -A 4 is independently hydroxamic acid or hydroxamate; -A 5 is independently carboxamide or substituted carboxamide; -A 6 is independently aliphatic C 2-6 alkenyl, and is optionally substituted; and -A 7 is independently carboxy or C 1-4 alkyl-carboxylate;n nand its use in the synthesis of temozolomide and analogues thereof.

专利号:US-2004101523-A1
优先权日:1989-07-27
标题:Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension
发明人：REITZ DAVID B; KOEPKE JOHN P; BLAINE EDWARD H; SCHUH JOSEPH R; MANNING ROBERT E; SMITS GLENN J
权利人:SEARLE & CO
摘要:Renal-selective prodrugs are described which are preferentially converted in the kidney to compounds capable of inhibiting synthesis of catecholamine-type neurotransmitters involved in renal sympathetic nerve activity. The prodrugs described herein are derived from inhibitor compounds capable of inhibiting one or more of the enzymes involved in catecholamine synthesis, such compounds being classifiable as tyrosine hydroxylase inhibitors, or as dopa-decarboxylase inhibitors, or as dopamine-β-hydroxylase inhibitors. These inhibitor compounds are linked to a chemical moiety, such as a glutamic acid derivative, by a cleavable bond which is recognized selectively by enzymes located predominantly in the kidney. The liberated inhibitor compound is then available in the kidney to inhibit one or more of the enzymes involved in catecholamine synthesis. Inhibition of renal catecholamine synthesis can suppress heightened renal nerve activity associated with sodium-retention related disorders such as hypertension. Conjugates of particular interest are glutamyl derivatives of dopamine-β-hydroxylase inhibitors, of which N-acetyl-γ-glutamyl fusaric acid hydrazide (shown below) is preferred.

专利号:WO-9101724-A1
优先权日:1989-07-27
标题 :Renal-selective prodrugs for the treatment of hypertension
发明人：REITZ DAVID B; KOEPKE JOHN P; BLAINE EDWARD H; SCHUH JOSEPH R; MANNING ROBERT E; SMITS GLENN J
权利人:SEARLE & CO
摘要:Renal-selective prodrugs are described which are preferentially converted in the kidney to compounds capable of inhibiting synthesis of catecholamine-type neurotransmitters involved in renal sympathetic nerve activity. The prodrugs described herein are derived from inhibitor compounds capable of inhibiting one or more of the enzymes involved in catecholamine synthesis, such compounds being classifiable as tyrosine hydroxylase inhibitors, or as depa-decarboxylase inhibitors, or as dopamine-β-hydroxylase inhibitors. These inhibitors compounds are linked to a chemical moiety, such as a glutamic acid derivative, by a cleavable bond which is recognized selectively by enzymes located predominantly in the kidney. The liberated inhibitor compound is then available in the kidney to inhibit one or more of the enzymes involved in catecholamine synthesis. Inhibition of renal catecholamine synthesis can suppress heightened renal nerve activity associated with sodium-retention related disorders such as hypertension. Conjugates of particular interest are glutamyl derivatives of dopamine-β-hydroxylase inhibitors, of which N-acetyl-Y-glutamyl fusaric acid is preferred.

专利号:WO-9201667-A1
优先权日:1990-07-25
标题 :Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
发明人：REITZ DAVID B; KOEPKE JOHN P; BLAINE EDWARD H; SCHUH JOSEPH R; MANNING ROBERT E; SMITS GLENN J
权利人:SEARLE & CO
摘要:Renal-selective prodrugs are described which are preferentially converted in the kidney to compounds capable of inhibiting synthesis of catecholamine-type neurotransmitters involved in renal sympathetic nerve activity. The prodrugs described herein are derived from inhibitor compounds capable of inhibiting one or more of the enzymes involved in catecholamine synthesis, such compounds being classifiable as tyrosine hydroxylase inhibitors, or as dopa-decarboxylase inhibitors, or as dopamine-β-hydroxylase inhibitors. These inhibitor compounds are linked to a chemical moiety, such as a glutamic acid derivative, by a cleavable bond which is recognized selectively by enzymes located predominantly in the kydney. The liberated inhibitor compound is then available in the kidney to inhibit one or more of the enzymes involved in catecholamine synthesis. Inhibition of renal catecholamine synthesis can suppress heightened renal nerve activity associated with sodium-retention related disorders such as hypertension. Conjugates of particular interest are glutamyl derivatives of dopamine-β-hydroxylase-inhibitors, of which N-acetyl-η-glutamyl fusaric acid hydrazide [represented in formula (a)] is preferred.